INOVIQ completed its share purchase plan, with total applications amounting to $7.3 million, surpassing its initial target of $2 million.

The company accepted allocations up to $2.4 million, resulting in a total capital raise of $9.4 million, including a prior placement to institutional investors.

Eligible shareholders were offered the chance to purchase new shares at 50 cents per share. Investors received one free quoted option for every two new shares issued, with an exercise price of $1 expiring on July 8, 2026.

The raised funds will be allocated to advancing EXO-NET research tools, developing pipeline diagnostics, and expediting cancer therapeutics research.